Document Detail

Aliskiren reduces home blood pressure and albuminuria in patients with hypertensive nephrosclerosis.
MedLine Citation:
PMID:  23135868     Owner:  NLM     Status:  Publisher    
BACKGROUND: The aim of this study was to investigate the antialbuminuric and antihypertensive effects of aliskiren by monitoring home blood pressure (BP) in comparison with the effects of the angiotensin receptor blocker (ARB) valsartan in patients with hypertensive nephrosclerosis and albuminuria. METHODS: We conducted an open-label, randomized trial to compare the effects of aliskiren with those of valsartan. Patients with BP <150/90 mmHg, an estimated glomerular filtration rate of 90-30 mL/min/1.73 m(2), and albuminuria >30 mg/g, despite treatment with a 160 mg daily dose of valsartan, were randomly assigned to the following two groups: the aliskiren group, who switched from 160 mg/day valsartan to 150 mg/day aliskiren, which was later increased to 300 mg/day (n = 20); and the valsartan group, who continued with 160 mg/day valsartan (n = 20). RESULTS: After 12 weeks of treatment, although there was no significant difference in clinic BP between groups, a significant reduction in morning and evening systolic BP was observed in the aliskiren group. The decrease in albuminuria in the aliskiren group was significantly better than that in the valsartan group, and a significant correlation was noted between the change in morning systolic BP and the change in albuminuria in the aliskiren group (r = 0.564, P = 0.0084). CONCLUSION: We showed that aliskiren treatment leads to a greater reduction in albuminuria and home systolic BP values than valsartan in patients with nephrosclerosis. We propose that aliskiren therapy should be considered as a therapeutic modality to complement ARBs in hypertensive patients with nephrosclerosis.
Hiroko Suzuki; Kazuyoshi Okada; Masanori Abe; Noriaki Maruyama; Yoshinori Yoshida; Seishiro Baba; Hiroyuki Takashima; Masayoshi Soma
Related Documents :
18070828 - Biologically effective dose using reciprocal repair for varying fraction doses and frac...
19634438 - Phosphorus fractions and its release in the sediments of haihe river, china.
18363378 - Perennisosides i-vii, acylated triterpene saponins with antihyperlipidemic activities f...
1478558 - Morphometric ultrastructural evaluation of secondary oocytes of mice receiving vincrist...
1549198 - Clinical studies with and pharmacokinetic considerations of sustained-release levodopa.
19498248 - [estimation of effective dose to salivary glands at examination of the oral and maxillo...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-11-9
Journal Detail:
Title:  Clinical and experimental nephrology     Volume:  -     ISSN:  1437-7799     ISO Abbreviation:  Clin. Exp. Nephrol.     Publication Date:  2012 Nov 
Date Detail:
Created Date:  2012-11-8     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9709923     Medline TA:  Clin Exp Nephrol     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Division of Nephrology, Hypertension and Endocrinology, Department of Internal Medicine, Nihon University School of Medicine, 30-1 Oyaguchi Kami-chou, Itabashi-ku, Tokyo, 173-8610, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  A girl with difficult lupus nephritis: lupus vasculopathy.
Next Document:  Commercial activities and the promotion of health in schools.